January 2023
-
Media Release Achievements and AnnouncementsCareersNovartis Healthcare Philippines recognized as a Top Employer for third consecutive yearNovartis Healthcare Philippines has been officially recognized by the Top Employers Institute as a Top Employer 2023 in the Philippines. To become recognized as a Top Employer, an organization must…
-
Media Release Partnerships and CommitmentsBreast CancerICanServe, Taguig City, Dashlabs, Novartis launch data-digital project to support breast cancer control programThe ICanServe Foundation, City of Taguig, local healthcare software startup Dashlabs, and Novartis have launched the Circle of Life Data and Digital Infrastructure project to support the Ating…
November 2022
-
Media ReleaseNovartis partners with DOH, medical societies, hospitals to strengthen healthcare system and improve heart failure management in PHIn a developing country like the Philippines, where healthcare delivery is mostly paid through patients' out-of-pocket expenses, the economic burden of heart failure (HF), especially hospitalization…
-
Media ReleaseNovartis recognized for supporting eye health services amid pandemicNovartis Healthcare Philippines was recognized by the National Committee for Sight Preservation (NCSP) for the company’s support to the NCSCP “Maging MATAlino”…
September 2022
-
Media ReleasePhilippine FDA approves Novartis drug, ribociclib, for advanced breast cancer in malesThe Philippine Food and Drug Administration (FDA) has approved ribociclib for the treatment of metastatic breast cancer. Ribociclib in combination with an aromatase inhibitor or fulvestrant can be…
-
Story
Novartis supports the Southeast Asian Breast Cancer Symposium
August 2022
-
Media ReleaseAlliance and Partnerships for Patient Innovation and Solutions (APPIS) Initiative announces winners of inaugural Innovator ProgramThe APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support, networking…
-
Media ReleaseNovartis hails Philippine FDA approval of brolucizumab treatment for age-related macular degeneration in time for Sight Saving MonthThe Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…
July 2022
-
Media ReleaseNovartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy lifePsoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help their…
-
Media ReleaseExperts encourage women with advanced breast cancer to get tested for PIK3CA mutation to improve treatment outcomesGenetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized…
-
Media ReleasePhilippine FDA approves Novartis advanced breast cancer treatment, alpelisibThe Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…